PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Drug combination may provide option to patients with NSCLC ineligible for bevacizumab

2012-04-04
(Press-News.org) CHICAGO — A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.

"The combination of carboplatin and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in patients with non-small cell lung cancer (NSCLC) ineligible for therapy with bevacizumab," said Gregory A. Otterson, M.D., professor of internal medicine, co-director of the thoracic oncology program and associate director of the hematology and medical oncology fellowship program at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio.

Otterson and colleagues evaluated the drug combination in 63 patients with advanced NSCLC. Seventy-six percent of patients had squamous histology, making them ineligible for bevacizumab. Other contraindications for bevacizumab among this patient population included hemoptysis, thrombosis and therapeutic anticoagulation. Researchers assigned patients to 300 mg/m2/AUC6, which was later adjusted to 260 mg/m2/AUC6 due to excess neuropathy, every 21 days.

Researchers found an overall response rate of 41 percent among 53 patients available for evaluation. An additional 39 percent of patients had stable disease for at least six weeks. Disease progressed in 19 percent of patients.

"We have been surprised at the durability of response with some patients not requiring further treatment for at least six months," Otterson said.

More than 10 percent of patients had grade 3 to 4 toxicities, including hematologic toxicity, febrile neutropenia, infection, sensory neuropathy, dyspnea and dehydration; researchers reported four deaths as grade 5 toxicities. "This combination treatment should be an option, particularly for patients with squamous histology who have limited alternative options," Otterson said.

### Press registration for the AACR Annual Meeting 2012 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration.

Follow the AACR on Twitter: @aacr #aacr Follow the AACR on Facebook: http://www.facebook.com/aacr.org

About the AACR Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR's membership includes 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 18,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of individual and team science grants in cancer research that have the potential for patient benefit. The AACR actively communicates with legislators and policy makers about the value of cancer research and related biomedical science in saving lives from cancer.

For more information about the AACR, visit http://www.AACR.org.

Presenter: Gregory A. Otterson, M.D.

Abstract Number: LB-225

Title: Phase 2 Trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies

Author Block: Erin M. Bertino, Miguel A. Villalona-Calero, Patrick Nana-Sinkam, Sarah Cantrel, Meliha Rahmani, Carrie Symmes, Gary S. Phillips, Gregory A. Otterson. Ohio State Univ. Comp. Cancer Ctr., Columbus, OH

Background: The addition of bevacizumab (Bev) to platinum based chemotherapy results in higher response rate (RR), progression-free survival (PFS), and overall survival (OS) in advanced non-small cell lung cancer (NSCLC). However, Bev is not indicated in patients (pts) with squamous histology or with hemoptysis due to bleeding risk,. Nab-paclitaxel is a novel formulation of paclitaxel with higher dose tolerance and potentially improved efficacy. A previous study of nab-paclitaxel/Carboplatin (using an alternative schedule) showed a higher response rate in patients with squamous histology (Socinski, et al, ASCO 2010, LBA7511). We hypothesized that in pts with NSCLC ineligible for Bev therapy the combination of nab-paclitaxel and carboplatin (Cb) would be superior to alternative doublets.

Methods: We conducted a single-arm, single-institution phase 2 trial (NCT00729612) to evaluate RR (primary endpoint), safety/toxicity, and survival (OS, PFS - secondary endpoints) in patients treated with nab-paclitaxel and carboplatin (Cb). Eligible pts included: squamous histology, history of hemoptysis, requirement for anticoagulation. Correlative studies included blood microRNA profiles pre-treatment. Treatment was administered every 21 days, initially at 300 mg/m2/AUC=6, but then adjusted to 260 mg/m2/AUC6 due to excess neuropathy.

Results: 63 pts (21 female, 42 male) with median age 63 yrs (range 36-82) were enrolled. Pts had an average 50 pk-yrs tobacco use. The most common histology was squamous cell carcinoma (48 pts/76%), followed by adenocarcinoma (9 pts/14%), NSCLC NOS (4 pts/6%) and adenosquamous (2 pts/3%). In non-squamous pts, eligibility criteria included hemoptysis (11 pts), thrombosis (2 pts), and therapeutic anticoagulation (1 pt). Grade 3-4 toxicities seen in more than 10% of pts included hematologic toxicity (36 pts/57%), febrile neutropenia (9/14%), infection (15/24%), sensory neuropathy (17/27%), dyspnea (10/16%) and dehydration (8/13%). Four deaths_including 1 sudden death and 1 death due to respiratory failure_were reported on study as grade 5 toxicity. ORR was 41% (22 PR/0 CR) in the 53 pts evaluable to date with 39% (21 pts) stable disease and 19% (10 pts) progressive disease. PFS/OS data is not yet available.

Conclusions: The combination of Cb and nab-paclitaxel demonstrates promising efficacy with tolerable toxicity in NSCLC pts ineligible for Bev therapy. Further study in the squamous cell population is warranted. Correlative studies of microRNA profiles and survival data (OS and PFS) is maturing and will be available in the near future.



ELSE PRESS RELEASES FROM THIS DATE:

"Vampire Zoo": British Film is Collaborative Effort of Creative Team

"Vampire Zoo": British Film is Collaborative Effort of Creative Team
2012-04-04
The trailer for a new British film reveals an edgy and sophisticated work of cinematography which will likely interest wide audiences in the United States as well as the UK. Stunning music, scenes, acting, and photography combine to make this a gem in the genre of independent films. Vampire Zoo has been written as a 6 part TV series and also a feature film. The creative team behind Vampire Zoo is comprised of a coalition of filmmakers - Clockwork Productions, JTMR Films and Foot in the Door Productions - who are attempting to raise the funds to make the project independently ...

Cruciferous vegetable consumption linked to improved breast cancer survival rates

2012-04-04
CHICAGO — Eating cruciferous vegetables after breast cancer diagnosis was associated with improved survival among Chinese women, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. "Breast cancer survivors can follow the general nutritional guidelines of eating vegetables daily and may consider increasing intake of cruciferous vegetables, such as greens, cabbage, cauliflower and broccoli, as part of a healthy diet," said Sarah J. Nechuta, M.P.H., Ph.D., a postdoctoral research fellow at Vanderbilt University in Nashville, Tenn. She ...

Baseline hormone levels may predict survival in metastatic, castration-resistant prostate cancer

2012-04-04
CHICAGO — Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. If confirmed, these data mean that levels of hormones, specifically adrenal androgens, may provide physicians with another way to predict the efficacy of therapy in patients with metastatic, castration-resistant prostate cancer, according to Charles J. Ryan, ...

Young women at growing risk of drunk-driving crashes

2012-04-04
PISCATAWAY, NJ – Underage female drinkers have been at a growing risk of fatal car crashes in recent years -- so much that they've caught up with their male counterparts, according to a study in the May issue of the Journal of Studies on Alcohol and Drugs. Back in 1996, the U.S. had a gender split when it came to underage drinkers' odds of being involved in a fatal car crash: at any given blood-alcohol level, young men had a higher risk of a fatal crash than young women did. But by 2007, the new study found, that gender gap had closed. The exact reasons are not clear. ...

Credible medical evidence of widespread torture in Darfur

2012-04-04
Allegations of widespread, sustained torture and other human rights violations by the Government of Sudan and Janjaweed forces against non-Arabic-speaking civilians are corroborated in a study published in this week's PLoS Medicine. In the study medical forensic experts reviewed the medical records of patients seen at a clinic in Darfur. The authors, co-led by Alexander Tsai based at Harvard University and Mohammed Eisa based at Physicians for Human Rights, both in Cambridge, USA, conclude: "The widespread, organized, and sustained pattern of attacks documented in our ...

Increasing height and body mass index are risk factors for ovarian cancer

2012-04-04
A study in this week's PLoS Medicine suggests that increasing height and, among women who have never taken menopausal hormone therapy, increased body mass index are risk factors for developing ovarian cancer. These findings are important as in high income countries, the average height and average body mass index of women have increased by about 1 cm and 1 kg/m2 respectively per decade. These findings suggest that if all other factors that affect ovarian cancer risk had remained constant, the increases in height and weight among women would have resulted in ovarian cancer ...

Priorities for health systems strengthening efforts from the US CDC

2012-04-04
In this week's PLoS Medicine, Peter Bloland and colleagues from the US Centers for Disease Control and Prevention (CDC) lay out the agency's priorities for health systems strengthening efforts. To guide its support of public health in low- and middle-income countries around the world, the CDC proposes to focus its investments on strengthening six key public health functions that would contribute the most towards health systems strengthening efforts as a whole and have the greatest impact on improving the public's health. These include ensuring the availability of critical ...

Scientists at Fox Chase discover link between estrogen and tobacco smoke

2012-04-04
CHICAGO, IL (April 3, 2012)––The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new research presented at the AACR Annual Meeting 2012 on Tuesday, April 3 by scientists at Fox Chase Cancer Center in Philadelphia. "This research provides the link between estrogen and tobacco smoke," says study author Jing Peng, Ph.D., postdoctoral associate in the lab of Margie L. Clapper, Ph.D., also a co-author on the paper. The ...

The World's Premier Fiberglass Working Boat - Polaris

The Worlds Premier Fiberglass Working Boat - Polaris
2012-04-04
The world's first fiberglass working boat, Polaris, was built by SHING SHENG FA BOAT BUILDING CO., LTD. (SSF), one of the boat builders who's been manufacturing and customizing boats for more than 41 years. SSF is recognized as a pioneer in designing and manufacturing workboats and vessels. Their workboats are designed specifically to achieve various challenges in order to present the best. SSF has been building workboats including fishery trials, oceanographic survey ships, oil spill prevent boats, patrol working boats, river working boats, etc. And their strong working ...

New compound targets key mechanism behind lymphoma

2012-04-04
CHICAGO, IL (April 3, 2012)––Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3. "It's an exciting time to be involved in lymphoma treatment and research," says study author Mitchell Smith, M.D., Ph.D., director of Lymphoma Service at Fox Chase. "There's a new understanding of the disease, and new drugs to treat it. I am optimistic that over the next couple of years treatments will continue ...

LAST 30 PRESS RELEASES:

Post-LLM era: New horizons for AI with knowledge, collaboration, and co-evolution

“Sloshing” from celestial collisions solves mystery of how galactic clusters stay hot

Children poisoned by the synthetic opioid, fentanyl, has risen in the U.S. – eight years of national data shows

USC researchers observe mice may have a form of first aid

VUMC to develop AI technology for therapeutic antibody discovery

Unlocking the hidden proteome: The role of coding circular RNA in cancer

Advancing lung cancer treatment: Understanding the differences between LUAD and LUSC

Study reveals widening heart disease disparities in the US

The role of ubiquitination in cancer stem cell regulation

New insights into LSD1: a key regulator in disease pathogenesis

Vanderbilt lung transplant establishes new record

Revolutionizing cancer treatment: targeting EZH2 for a new era of precision medicine

Metasurface technology offers a compact way to generate multiphoton entanglement

Effort seeks to increase cancer-gene testing in primary care

Acoustofluidics-based method facilitates intracellular nanoparticle delivery

Sulfur bacteria team up to break down organic substances in the seabed

Stretching spider silk makes it stronger

Earth's orbital rhythms link timing of giant eruptions and climate change

Ammonia build-up kills liver cells but can be prevented using existing drug

New technical guidelines pave the way for widespread adoption of methane-reducing feed additives in dairy and livestock

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

New study finds that tooth size in Otaria byronia reflects historical shifts in population abundance

nTIDE March 2025 Jobs Report: Employment rate for people with disabilities holds steady at new plateau, despite February dip

Breakthrough cardiac regeneration research offers hope for the treatment of ischemic heart failure

Fluoride in drinking water is associated with impaired childhood cognition

New composite structure boosts polypropylene’s low-temperature toughness

While most Americans strongly support civics education in schools, partisan divide on DEI policies and free speech on college campuses remains

Revolutionizing surface science: Visualization of local dielectric properties of surfaces

LearningEMS: A new framework for electric vehicle energy management

Nearly half of popular tropical plant group related to birds-of-paradise and bananas are threatened with extinction

[Press-News.org] Drug combination may provide option to patients with NSCLC ineligible for bevacizumab